BioWorld Asia

March 23, 2011

Genfit, Sanofi-Aventis Ink $54M Deal for Metabolic Disorders

Extending a partnership that dates back to 1999, Genfit, of Lille, France, has inked an agreement with Sanofi-Aventis SA, of Paris, to pursue therapies for the treatment of metabolic disorders. (BioWorld International) Read More

Scotland Aims to Double its Life Sciences Sector by 2020

Agennix Finishes Recruitment for NSCLC Drug's Phase III

Ion Channel on Sperm Could Be Key to New Contraceptives

Transgene Sets Game Plan for Cancer Vaccine Post-Roche Exit

Amgen's BioVex Buy Prompts PsiOxus to Expand its Program

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...

HMNC raises $50M series B to prep depression drugs for phase III

BioWorld

HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...